Chargement en cours...
CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer?
The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors palbociclib, ribociclib, and abemaciclib are rapidly transforming the care of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) advanced breast cancer. Current clinical questions...
Enregistré dans:
| Publié dans: | Oncology (Williston Park) |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6424488/ https://ncbi.nlm.nih.gov/pubmed/29847850 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|